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Dear Editor.
We read with great interest the paper of Cheng et al.
[1]. They demonstrate for the first time as anti-cyclic
citrullinated peptides antibodies (Anti-CCP) are an inde-
pendent risk factor for fracture and this data is of high
clinical relevance in stratifying rheumatoid arthritis (RA)
patients. The authors have a wide population and were
able to take into consideration a lot of factors involved in
bone disease related and unrelated to RA. They did con-
firm our previous reports of a negative effect of Anti-CCP
on BMD [2], and also showed a relation with FRAX
10 year calculated fracture risk. In particular, the BMD dif-
ference was observed at femoral neck, site of cortical bone
that is the same of periarticular bone were erosions occur
[3, 4]. Nevertheless, the Authors failed to find any correl-
ation between Anti-CCP titer and BMD. This last data is
in contrast with other previous clinical reports of a titer
dependent effect of Anti-CCP on bone [2, 5].
The reasons of these discrepancies are not straightfor-
ward. A possible explanation of lack of correlation be-
tween Anti-CCP titer and BMD could be the use of BMD
as g/cm2 and not as Z-score in the analysis. Z-score has
the advantage to evaluate better the bone loss correcting
for age and gender. Another possible confounder is the
evaluation of glucocorticoids (GCs) as a dichotomous
variable. It is not clear how the patients were considered
“users” and there were no data on mean dose or duration
of use, thus of a cumulative dose. The Authors report also
data on anti-osteoporosis medications, but they are un-
specified, even if they probably refer to antiresorptive
drugs. Moreover, data on vitamin D and calcium, either
supplements and serum levels, are completely lacking.
Vitamin D and PTH are key determinants of cortical bone
(e.g. femoral neck) mass [3], so their inclusion in the ana-
lysis would have been of critical importance.
We think the paper is of great interest but that some
of the variables taken into consideration should be im-
plemented and that a more complex statistical analysis is
needed to take the best from its data.
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